12:00 AM
 | 
Feb 20, 2012
 |  BC Week In Review  |  Company News  |  Deals

Eyetech, Valeant Pharmaceuticals deal

Valeant will acquire Eyetech for an undisclosed upfront payment and potential milestones. Valeant will gain Macugen pegaptanib,...

Read the full 71 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >